Latest news with #HSCs
Yahoo
12-06-2025
- Business
- Yahoo
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June
Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement supports development of a novel, in vivo approach to treating sickle cell disease and beta thalassemia. CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today shared new in vivo data demonstrating therapeutically relevant levels of HBG1/2 promoter editing in hematopoietic stem cells (HSCs) with a single dose of proprietary targeted lipid nanoparticle (tLNP) in non-human primates (NHPs). This clinically validated approach targeting HBG1/2 promoters to upregulate fetal hemoglobin (HbF) is in pre-clinical development as a potential transformative in vivo gene editing medicine for the treatment of sickle cell disease and beta thalassemia. The Company reported these data in a presentation available today and will detail the data in a poster session on Saturday, June 14th 6:30 - 7:30 p.m. CEST (12:30 – 1:30 p.m. EDT) at the European Hematology Association (EHA) 2025 Congress in Milan, Italy. In this study, the Company's proprietary tLNP formulation delivered HBG1/2 promoter editing cargo to HSCs in NHPs. Latest data from this ongoing NHP study showed that at five months a single intravenous administration of Editas' tLNP resulted in mean on-target editing levels in the HBG1/2 promoter region of 58% in HSCs: well exceeding the predicted editing threshold of ≥25% required for therapeutic benefit. In addition to achieving therapeutically relevant editing levels, the biodistribution data in NHPs with Editas' tLNP continue to show significant de-targeting of the liver in contrast to standard LNPs. 'These data from our in vivo HSC program confirm our ability to achieve high efficiency delivery, therapeutically relevant editing levels and favorable biodistribution in NHPs. These data validate the further development of Editas' proprietary HSC-tLNP for editing of the HBG1/2 promoters for the treatment of sickle cell disease and beta thalassemia,' said Linda C. Burkly, Ph.D., Executive Vice President and Chief Scientific Officer, Editas Medicine. Editas Medicine's in vivo HSC program targets HBG1/2 promoters to mimic naturally occurring mechanisms of hereditary persistence of fetal hemoglobin (HPFH) and utilizes proprietary AsCas12a to edit with high efficiency and minimize off-target editing. Editing the HBG1/2 promoters with AsCas12a with the investigational medicine reni-cel led to robust increases in HbF and total hemoglobin (Hb) in clinical trials. The presentation details are listed below. Abstracts can be accessed on the EHA website, and the presentation will be posted on the Editas Medicine website during the conference. Poster Presentation Details: Title: Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for β-hemoglobinopathies Date/Time: Saturday, June 14, 2025, 6:30 - 7:30 p.m. CEST/ 12:30 – 1:30 p.m. EDT Location: Allianz MiCo, Milano Convention Centre Session: Poster Session 2 About Editas Medicine As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute's Cas12a patent estate and Broad Institute and Harvard University's Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit CONTACT: Media and Investor Contacts: media@ ir@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Time of India
27-05-2025
- Health
- Time of India
Delhi pilgrim dies during Yamunotri trek, Char Dham yatra death toll crosses 40
Dehradun: A 46-year-old man from Delhi's Mandoli area died of cardiopulmonary arrest on Tuesday while on the Yamunotri yatra. Shiv Kumar collapsed while taking a selfie around 1km from the Yamunotri shrine. His death marks the 43rd fatality on the Char Dham yatra, which began on April 30. Kumar's family and a health team took him to a community health centre in Janki Chatti, where doctors declared him dead. A school bus driver by profession, Kumar had completed the Char Dham yatra for two consecutive years. This year, he was undertaking the pilgrimage for the third time with five family members, said his nephew Lavkesh Kumar. Yamunotri was the first stop on their journey. Health officials attributed his death to cardiopulmonary arrest, likely triggered by strenuous trekking conditions and low oxygen levels near the Yamunotri shrine, which sits at an altitude of roughly 10,800 ft in the Garhwal Himalayas. With the rise in pilgrim footfall, there has been a steady increase in health-related deaths during the annual pilgrimage. The Kedarnath trek, which requires pilgrims to walk at least 16km uphill, has seen at least 20 fatalities. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like People Born 1940-1975 With No Life Insurance Could Be Eligible For This Reassured Get Quote Undo Ten pilgrims have died on the Yamunotri route, followed by eight in Gangotri and five in Badrinath, bringing the total number of deaths due to health complications to 43, according to district authorities. Officials deployed on the yatra route said stricter enforcement is needed in the plains, where some pilgrims "intentionally" bypass health checks to continue their journey. By the time health screenings are conducted in the hills, many have already entered high-risk zones, limiting the effectiveness of the process. "Most fatalities have occurred due to cardiac or respiratory issues, often triggered by pre-existing comorbidities that worsen in the region's harsh conditions, as all the shrines are above 10,000 ft. Like the Amarnath Yatra, we need mandatory health criteria to prevent such tragedies. At Amarnath, checks are strictly enforced due to security reasons. But since the Char Dham yatra doesn't face such threats, it remains open to all. This open access, however, needs to be reconsidered," said an official from the Char Dham district administration. Since April 30, approximately 349,111 pilgrims have undergone screenings at various Health Screening Centres (HSCs) and Medical Relief Points (MRPs) along the route. Of these, nearly 15,000 were identified with comorbidities, according to data from the Uttarakhand health department. "Pilgrims who believe that dying during the journey guarantees salvation (moksha) should be gently counselled to prioritise their health and aim for a safe pilgrimage. This approach would significantly help reduce the death toll," said a senior doctor on yatra duty. Health staff have counselled over 3,000 high-risk individuals flagged for comorbidities and nearly two dozen were convinced to return to their home states and attempt the pilgrimage later, once their health improved, according to the state health department data.
New Indian Express
04-05-2025
- Business
- New Indian Express
CCMC aims to wrap up work on 24x7 water supply project by August 2
COIMBATORE: After years of delays, missed deadlines, and mounting public frustration, the Coimbatore City Municipal Corporation (CCMC) is making a final push to complete the long-overdue 24x7 drinking water supply project by August 2 this year. The project, being implemented across 60 wards by private contractor Suez India Projects Pvt. Ltd., has been fraught with challenges since its inception in 2019. The Rs 646.71-crore initiative, launched through an agreement signed in 2018 between CCMC and Suez, was initially expected to be completed by August 2023. However, the COVID-19 pandemic, labour shortages, coordination lapses, and allegations of substandard work pushed the project off track, forcing the civic body to extend the deadline to August 2025. Now, with mounting pressure from the CCMC councillors in view of the assembly election in Tamil Nadu next year, the CCMC is determined to wrap up the project within the next three months. Despite the urgency, progress has been slow. Only around 82% of the work has been completed so far, with several wards still lagging behind. Councillors across zones have expressed disappointment over the poor execution and delays, particularly the inability to resume roadwork due to incomplete House Service Connections (HSCs). "As far as the Central Zone is concerned, the work is fully completed only in wards 31, 32, 46, and 47. In many other areas, Suez has left out 20 to 50 houses without HSCs, which is delaying road restoration. Without connecting all houses, we can't move ahead with road-laying," Central Zone Chairperson Meena Logu told TNIE. "Councillors are not happy with the quality of the work. The road surfaces are uneven, and the work is being done without proper supervision. All stakeholders - the public, councillors, CCMC, and Suez - should have coordinated better from the beginning."
